Time-Sensitive Opportunities for Health Research (R61/R33 Clinical Trial Not Allowed) **PAR-22-233**
Pre-Application Webinar, October 6, 2022: Question & Answer

#	Question	Answer
General Questions		
1	Will a recording or slide deck be available after the presentation?	Yes. The webinar slides, webinar recording, and FAQ document will be posted as soon as possible on the OBSSR website.
2	What is the page limit for the research strategy section?	As stated in the FOA, applications should follow page limitations described in the SF 424 Application Guide and the Table of Page Limits.
3	Will resubmissions be allowed?	No. Revisions will not be allowed for this funding opportunity, given the focus on time sensitive applications.
4	Is there a specific set-aside funding per IC that would make it more advantageous to apply early?	Each IC will be making funding decisions and dollar amounts by their own procedures, which may or may not include a set aside. Further questions about funding priorities and process should be addressed with the appropriate program officer. Since this is a mechanism with rolling receipt dates, the 11/1 deadline is provided as a starting point. Timing is more dependent on the nature of the time-sensitive event about which your research is based.
5	What payline will be used to determine if the application will get funded. The standard R01 payline for the Institute?	
6	Should we be providing letters of support for evidence of partnerships?	In general, reviewers benefit from seeing letters of support showing that applicants have established partnerships (particularly for primary partners applicants may already be working with).
7	How do we include partnerships within the budgeting and planning portion of the R61 phase?	Community partnerships should be incorporated into your proposal and budget as properly reflective of their roles, responsibilities, and contribution to the work.
PAR Background, Objectives, Expectations		
8	"Unexpected events" included pandemics. Does this include interest in research regarding the COVID pandemic, or do you expect to be moving away from funding COVID pandemic research?	For the purposes of this FOA, we urge applicants to carefully review the specific areas of research interest provided by participating ICOs for alignment with research proposals. We also urge applicants to explore existing ongoing and active funding opportunities that are COVID-specific and may be relevant and appropriate to specific research aims.
9	Many of these events happen so quickly and unexpectedly that there is no opportunity to collect baseline data (e.g., Hurricane Ian). How will the extent to which the project collects data at "true" baseline be considered?	This will be dependent on the research questions, research aims, and the type of event the application is in response to. Specific questions about timing of baseline data collection (or use of existing data) should be addressed with an ICO program officer ahead of application submission.
10	Are multi-institutional/PI proposals encouraged?	This would depend on the nature of the research questions and the group of institutions that may be coming together to answer proposed research questions.

11	Can investigators propose a dissemination aim? For example, 1-2 research aims to study impact of an event/policy/program and an aim focused on dissemination of results to impacted communities?	A dissemination aim may be allowable, but such questions should be discussed with the appropriate ICO Program Officer prior to application submission.
12	Does the R61 need to be a full year if much of the planning work would be done when started?	No. The R61 phase is for research support up to one year. If research milestones are met in an earlier timeframe than one year, it may be possible to proceed to the R33 phase provided additional requirements are met and funding is available. Alternatively, if the applicants do not anticipate taking a full year for planning and data collection, that timeline should be presented in the application.
13	Could you give an example of what an aim versus a milestone might be during the R61 period?	This information should be provided in the FOA and can be discussed in more detail with a Program Officer. In general, a milestone is much more specific and measurable than a research aim.
14	Is it okay to collect data during the R61 period?	Yes. However, as noted in the FOA, primary data collection is required to take place within 6 months of award.
15	Are projects that include primary data collection where enrollment will take place over more than a 6-month period eligible?	
16	What is the allowable budget for the projects?	Please see the FOA for specific budget information, and follow up with the appropriate Program Officer for further budget-related questions.
17	Can the 2 phases have equal budget levels?	
18	Are there any expectations about funding the R61 versus the R33 components?	The R61 portion of this funding opportunity is funded as a pilot to enable data collection and assess feasibility of the proposed research, As noted in the FOA, transition to, and funding for, the R33 phase is neither automatic nor guaranteed. Funding is subject to availability of funds and program priorities, independent of milestone achievement.
19	Who reviews whether milestones are met? The PO of main IC?	Typically there is a standard process for review of milestones in these types of applications involving an internal NIH team.
20	How many total proposals will you be funding?	There is no set number of total proposals that will be funded under this PAR.
21	Are there any efforts to apply an equity lens for the actual research team?	Every facet of the United States scientific research enterprise—from basic laboratory research to clinical and translational research to policy formation–requires superior intellect, creativity and a wide range of skill sets and viewpoints. NIH's ability to help ensure that the nation remains a global leader in scientific discovery and innovation is dependent upon a pool of highly talented scientists from diverse backgrounds who will help to further NIH's mission. For more information, please see the NIH Notice of Interest in Diversity (NOT-OD-20-031).
22	Have we funded [this type of research] in the past? Are there examples of previously funded topics?	We encourage you to search through NIH RePORTER for examples of past projects under the following FOAs:

		(1) NIEHS: Mechanism for Time-Sensitive Research Opportunities in Environmental Health Sciences (R21 Clinical Trial Not Allowed) [RFA-ES-19-011] (2) NIDDK, NCI, NICHD: Time-Sensitive Obesity Policy and Program Evaluation (R01 Clinical Trial Not Allowed) [PAR-18-854] (3) NIDA, NIAAA (: Mechanism for Time-Sensitive Drug Abuse Research (R21 Clinical Trial Optional) [PAR-19-064]
23	Is this FOA for the US setting only? Or is global health research supported?	Please refer to the funding opportunity announcement for specific information on eligibility for foreign institutions and investigations occurring outside of the U.S. Global health research may be allowed if certain conditions are met.
Questions related to Review		
24	How will study section review occur with a rolling deadline? Can you elaborate how study section participants will be compiled?	CSR will gather as many applications as is feasible within the timeframe available to meet the 8-week deadline. As always, reviewers will be selected based on their relevant expertise given the scientific content area and methodological approaches in the set of applications.
25	Will the review committee meet about every 8 weeks to review accumulated submissions and rank against one another?	